Our portfolio approach gives us the freedom to pursue a wider range of technologies, maximizing opportunities for growth and value creation. We develop new medical innovations we believe can make a significant clinical impact in improving the health of patients.
Our portfolio covers a range of technologies that focus on different therapeutic areas, which helps us to mitigate risk and create and build value.
Our two lead commercial technologies (MetaMx and ABP569) are both on track to enter human clinical trials in 2018.
Our scientists collaborate in a way that facilitates knowledge sharing across different technologies and therapeutic areas.